Clinical trials: Huntington's Disease
Huntington Disease
Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.
A better understanding of the HD pathogenesis mechanisms may lead to a better understanding of disease pathology, progression and development of targeted therapies.
- Trial name
- NCT05224115
- Testing
- [11C]CHDI-00485180-R, [11C]CHDI-00485626
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Huntington's Disease
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
Huntington's disease (HD) is a slowly progressive disorder that devastates the lives of those affected and their families. There are no treatments that slow the progression of HD, only mildly effective symptomatic therapies are…
- Trial name
- CREST-E (NCT00712426)
- Testing
- Creatine Monohydrate
- Where
- 47 sites in United States, Australia and 2 more
- Volunteers
- 553 people
- Sponsor
- Massachusetts General Hospital
Huntington Disease
Evaluation of Three Tests to Assess Social Cognition in Huntington Disease
The goal of this observational study is to learn about the usefulness of a test of social functioning in persons with Huntington disease.
- Trial name
- NCT07253038
- Where
- Sweden
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Region Skane
Huntington Disease
Pridopidine Phase 3 Study in Huntington's Disease
The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine.
- Trial name
- PRECISE-HD (NCT07609108)
- Testing
- Pridopidine
- Where
- 66 sites in United States, Belgium and 10 more
- Volunteers
- 400 people
- Sponsor
- Prilenia
Huntington Disease
31P-MRS and Huntington Disease
The purpose of this study is to identify and quantify a brain energy deficit in Huntington patients, using 31P-RMN spectroscopy.
- Trial name
- PRO-MH (NCT01359774)
- Testing
- 31P-MR spectroscopy, 31P-RMN spectroscopy
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Huntington Disease
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
- Trial name
- INVEST-HD (NCT07326709)
- Testing
- Votoplam (blinded)
- Where
- 117 sites in United States, Argentina and 25 more
- Volunteers
- 770 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease (HD)
Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self Feeding Behaviours in a Huntington's Disease Population
Primary Objectives To assess the acceptability of using the DoddleBags feeding aid in people with HD, by using a food diary to track food intake and using semi-structured interviews to ask questions about how easy or difficult it…
- Trial name
- FEEDhd (NCT07299682)
- Testing
- DoddleBags
- Where
- 7 sites in United Kingdom
- Sponsor
- University of Hull
Huntington Disease
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.
- Trial name
- NCT00146211
- Testing
- Ethyl-EPA (Miraxion™)
- Where
- 41 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Amarin Neuroscience Ltd
Huntington's Disease
Creatine Therapy for Huntington's Disease
This study, CREST-HD, will examine the safety and tolerability of 8 grams of creatine in subjects affected by Huntington's disease (HD).
- Trial name
- NCT00026988
- Testing
- Creatine
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Huntington Disease
A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease
In the study the investigators plan to include 100 early affected HD patients (5 ≤ UHDRS ≤ 40) in a randomized, double-blind, controlled study in 2 centers (France and the Netherlands).
- Trial name
- TRIHEP3 (NCT02453061)
- Testing
- Triheptanoin oil
- Where
- 2 sites in France, Netherlands
- Volunteers
- 100 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Huntington Disease
Study of WVE-003 in Patients With Huntington's Disease
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of WVE-003 in adult patients with early-manifest HD who…
- Trial name
- NCT05032196
- Testing
- SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003
- Where
- 23 sites in Australia, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington's Disease
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
PRECISION-HD1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120101 in…
- Trial name
- PRECISION-HD1 (NCT03225833)
- Testing
- WVE-120101
- Where
- 21 sites in Australia, Canada and 5 more
- Volunteers
- 61 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington's Disease
Coenzyme Q10 in Huntington's Disease (HD)
The goals of this trial are to determine if coenzyme Q10 is effective in slowing the worsening symptoms of Huntington's disease and to learn about the safety and acceptability of long-term coenzyme Q10 use by determining its…
- Trial name
- 2CARE (NCT00608881)
- Testing
- coenzyme Q10
- Where
- 49 sites in United States, Australia and 1 more
- Volunteers
- 609 people
- Sponsor
- Massachusetts General Hospital
Huntington Disease, Healthy
Digital Measures for Clinical Trial Endpoints in Huntington's Disease
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons.
- Trial name
- MEND-HD (NCT07010705)
- Testing
- ActiGraph LEAP, Axivity AX6
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Huntington Disease
Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon…
- Trial name
- NCT05243017
- Testing
- intra-striatal rAAV5-miHTT
- Where
- 4 sites in Poland, United Kingdom
- Volunteers
- 14 people
- Sponsor
- UniQure Biopharma B.V.
Chorea, Huntington
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
- Trial name
- NCT04400331
- Testing
- Valbenazine
- Where
- 34 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Neurocrine Biosciences
Huntington Disease
Bioavailability of Ubiquinol in Huntington Disease
The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals.
- Trial name
- NCT00980694
- Testing
- ubiquinol
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Rochester
Huntington Disease
Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Research
The Project AWARE 2.0 Survey is intended to gain knowledge about the feelings, attitudes, and beliefs of HD family members, care partners and others affected by HD towards the way drug trials and observational studies are…
- Trial name
- NCT06343220
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Huntington Study Group
Huntington Disease
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Positron Emission Tomography (PET) is a functional imaging technique, which enables in vivo visualization of biological molecules expressed in human tissues.
- Trial name
- NCT05360082
- Testing
- [11C]UCB-J PET, [18F]SynVest-1 PET
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Huntington Disease
Nilotinib in Huntington's Disease
Based on strong pre-clinical evidence of the effects of Nilotinib on neurodegenerative pathologies, including autophagic clearance of neurotoxic proteins, neurotransmitters (dopamine and glutamate), immunity and behavior, the…
- Trial name
- Tasigna HD (NCT03764215)
- Testing
- Nilotinib 150 MG
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Georgetown University